Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6763 |
Xevinapant
ARRY-334543,SM-406,AT406,Debio-1143 |
IAP | Apoptosis |
Xevinapant (Debio-1143) 是一种有效的 Smac 模拟物和 IAP 的拮抗剂,能够抑制 XIAP,cIAP1 和 cIAP2 蛋白,Ki 值分别为 66.4,1.9 和 5.1 nM。 | |||
T3299 |
Xevinapant hydrochloride
AT-406 HCl,SM-406 |
Apoptosis; IAP | Apoptosis |
Xevinapant hydrochloride (AT-406 HCl) 是口服生物可利用的 Smac 模拟物,也是细胞凋亡蛋白抑制剂的拮抗剂。它在无细胞功能测定中有效拮抗 XIAP BIR3 蛋白,诱导细胞 cIAP1 蛋白的快速降解,并抑制各种人类癌细胞系中的癌细胞生长。它在诱导异种移植肿瘤细胞凋亡方面非常有效。 | |||
T6174 |
R406
R-406 besylate |
Apoptosis; FLT; Syk | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
R406 (R-406 besylate) 是一种具有口服活性的 ATP 竞争性 Syk/FLT3抑制剂,Ki 为 30 nM。它有效抑制 Syk 激酶活性,IC50为 41 nM。它还抑制 Lyn 和 Lck,IC50值分别为 63 nM 和 37 nM。它可减轻免疫复合物介导的炎症。 | |||
T2467 |
R406 free base
R406 (free base) |
Apoptosis; FLT; Syk | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
R406 free base (R406(free base)) 是一种具有口服活性的,ATP 竞争性的Syk/FLT3抑制剂,Ki 为 30 nM。它有效抑制 Syk 激酶活性,IC50为 41 nM,可减轻免疫复合物介导的炎症。它还抑制 Lyn 和 Lck,IC50分别为 63 nM 和 37 nM。 | |||
T8694 |
ML406
|
Antibacterial; Antibiotic | Microbiology/Virology |
ML406 是一种小分子探针,通过抑制M.tuberculosisBioA(DAPA 合酶) 显示出抗结核活性,IC50为 30 nM。 | |||
T125653 |
USF 406B
|
||
T70168 |
Tofacitinib HCl
|
||
Tofacitinib, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. | |||
T69958 | Tofacitinib maleate | ||
Tofacitinib, also known as tasocitinib, CP-690550, is a Janus kinase (JAK) inhibitor. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the in vitro activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC50 of 406, 56, and 1377 nM, respectively. |